Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.57−0.08 (-1.50%)
Close on Nov 17, 2026Market cap $482.87MP/E –Yield –
Valneva operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Valneva's operating cash flow for the twelve months ending Jun 30, 2026 was -€55.69M. For fiscal 2025 it was -€52.89M. The highest annual figure on record is €137.74M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€52.89M | – |
| FY2024 | Dec 31, 2024 | -€67.22M | – |
| FY2023 | Dec 31, 2023 | -€202.74M | – |
| FY2022 | Dec 31, 2022 | -€245.34M | -419.0% |
| FY2021 | Dec 31, 2021 | €76.90M | -44.2% |
| FY2020 | Dec 31, 2020 | €137.74M | +2391.2% |
| FY2019 | Dec 31, 2019 | €5.53M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€13.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -€313.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -€24.51M | -357.3% |
| Q3 FY2025 | Sep 30, 2025 | -€17.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -€2.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -€8.15M | – |
| Q4 FY2024 | Dec 31, 2024 | €9.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -€10.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -€37.83M | – |
| Q1 FY2024 | Mar 31, 2024 | -€28.43M | – |
| Q4 FY2023 | Dec 31, 2023 | -€65.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -€71.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -€41.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -€24.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -€55.83M | -238.0% |
| Q3 FY2022 | Sep 30, 2022 | -€89.29M | – |
| Q2 FY2022 | Jun 30, 2022 | -€73.38M | -300.0% |
| Q1 FY2022 | Mar 31, 2022 | -€26.85M | -156.5% |
| Q4 FY2021 | Dec 31, 2021 | €40.45M | – |
| Q3 FY2021 | Sep 30, 2021 | -€47.80M | – |
| Q2 FY2021 | Jun 30, 2021 | €36.69M | – |
| Q1 FY2021 | Mar 31, 2021 | €47.56M | – |
See a number that looks wrong?